APO-GO PEN 10 Mg/Ml Solution for Injection Ireland - English - HPRA (Health Products Regulatory Authority)

apo-go pen 10 mg/ml solution for injection

genus pharmaceuticals limited - apomorphine hydrochloride - solution for injection - 10 mg/ml

APO-go PEN 30mg/3ml solution for injection United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

apo-go pen 30mg/3ml solution for injection

britannia pharmaceuticals ltd - apomorphine hydrochloride - solution for injection - 10mg/1ml

APO-go 20mg/2ml solution for injection ampoules United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

apo-go 20mg/2ml solution for injection ampoules

britannia pharmaceuticals ltd - apomorphine hydrochloride - solution for injection - 10mg/1ml

APO-go 50mg/5ml solution for injection ampoules United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

apo-go 50mg/5ml solution for injection ampoules

britannia pharmaceuticals ltd - apomorphine hydrochloride - solution for injection - 10mg/1ml

APO-go PFS 50mg/10ml solution for infusion pre-filled syringes United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

apo-go pfs 50mg/10ml solution for infusion pre-filled syringes

britannia pharmaceuticals ltd - apomorphine hydrochloride - solution for infusion - 5mg/1ml

APOWOK apomorphine hydrochloride hemihydrate 10 mg/mL solution for injection or infusion ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

apowok apomorphine hydrochloride hemihydrate 10 mg/ml solution for injection or infusion ampoule

wockhardt bio pty ltd - apomorphine hydrochloride hemihydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium metabisulfite; sodium hydroxide; hydrochloric acid; water for injections - apowok solution for injection or infusion is indicated to reduce the number and severity of ?off? phases in patients with parkinson?s disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during ?on? phases.

MOVAPO PEN apomorphine hydrochloride hemihydrate 30 mg/3 mL Solution for Injection, Cartridge Australia - English - Department of Health (Therapeutic Goods Administration)

movapo pen apomorphine hydrochloride hemihydrate 30 mg/3 ml solution for injection, cartridge

stada pharmaceuticals australia pty ltd - apomorphine hydrochloride hemihydrate, quantity: 30 mg - injection, solution - excipient ingredients: sodium metabisulfite; hydrochloric acid; water for injections - movapo pen is indicated to reduce the number and severity of 'off' phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during 'on' phases.

APO-Levetiracetam Oral levetiracetam 100 mg/mL amber glass bottle Australia - English - Department of Health (Therapeutic Goods Administration)

apo-levetiracetam oral levetiracetam 100 mg/ml amber glass bottle

southern cross pharma pty ltd - levetiracetam, quantity: 100 mg/ml - solution - excipient ingredients: propyl hydroxybenzoate; maltitol; purified water; sodium citrate dihydrate; glycerol; ammonium glycyrrhizinate; methyl hydroxybenzoate; acesulfame potassium; citric acid monohydrate; flavour - apo-levitiracetam oral solution is indicated for:,? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment,of partial onset seizures with or without secondary generalisation,,? monotherapy in the treatment of partial onset seizures, with or without secondary,generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,? add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12,years of age with juvenile myoclonic epilepsy (jme),,? add-on therapy in the treatment of primary generalized tonic clonic (pgtc) seizures in adults and,children from 4 years of age with idiopathic generalized epilepsy (ige).

APOMINE Intermittent apomorphine hydrochloride hemihydrate 30mg/3mL injection cartridge Australia - English - Department of Health (Therapeutic Goods Administration)

apomine intermittent apomorphine hydrochloride hemihydrate 30mg/3ml injection cartridge

interpharma pty ltd - apomorphine hydrochloride hemihydrate, quantity: 10 mg - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; sodium hydroxide; hydrochloric acid - apomorphine injection is indicated to reduce the number and severity of "off" phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine injection should be undertaken by a specialist unit in a hospital setting. conventional therapy should be continued during "on" phases.

Apovomin 3 mg/ml inj. sol. s.c. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

apovomin 3 mg/ml inj. sol. s.c. vial

dechra regulatory b.v. - apomorphine hydrochloride 3 mg/ml - eq. apomorphine 2,56 mg/ml - solution for injection - 3 mg/ml - apomorphine hydrochloride 3 mg/ml - apomorphine - dog